It was also suggested that mucoepidermoid carcinoma patients might benefit from combination therapy with an inhibitor of IL-6R signaling and chemotherapeutic agent such as paclitaxel42. The gene discussed is IL6R; the disease is mucoepidermoid carcinoma.